Omeros Corp said on Monday its experimental treatment helped six patients, with acute respiratory distress syndrome caused by COVID-19, recover and get discharged from the hospital, sending the drug developer’s shares up 60%.
The company said it was in talks with the U.S. government for potential funding to speed up large-scale manufacturing for broader availability of the treatment, narsoplimab.
All six patients had underlying conditions and needed mechanical ventilation before treatment, Omeros said.
Acute respiratory distress syndrome, or ARDS, causes fluid to collect in the lungs, depriving organs of oxygen. COVID-19 patients with ARDS often require intensive care.
I run this site in my spare time and thoroughly enjoy giving you all positive news! If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.